Common Contracts

Licensing and option agreement for antibody program

License Agreement • April 23rd, 2023 • New York

• Contract Type
  License Agreement
• Filed
  April 23rd, 2023
• Jurisdiction
  New York

This includes upfront, clinical and regulatory milestone payments. Inhibrx is eligible to receive royalties on commercial sales.

Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...

License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  License Agreement
• Filed
  June 3rd, 2019
• Company
  Inhibrx, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This License Agreement (this “Agreement”) is made effective e as of July 1, 2013 (“Effective Date”) by and between INBRX 103, LLC, a limited liability company with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Inhibrx”), and Celgene Corporation a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”). Inhibrx and Licensee each may be referred to herein individually as a “Party” and together as the “Parties.”